Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-04-21

FDA Approved: ZYPREXA INTRAMUSCULAR — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved Eli Lilly's supplemental application for ZYPREXA Intramuscular (olanzapine), finalizing approval for the intramuscular formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZYPREXA INTRAMUSCULAR (olanzapine)

Snippet

SUPPL AP for ZYPREXA INTRAMUSCULAR (OLANZAPINE)